Glycitop-MR 30 Tablet contains Gliclazide 30 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glycitop-MR 30 is formulated as a modified-release tablet to provide a sustained therapeutic effect, enabling once-daily dosing and enhancing patient compliance. This medication is typically prescribed as an adjunct to diet and exercise when diet alone is insufficient to achieve adequate blood glucose control. It is important to monitor blood glucose levels regularly during treatment to avoid hypoglycemia, a potential adverse effect characterized by symptoms such as sweating, dizziness, and confusion. Dose adjustments may be necessary in patients with renal or hepatic impairment. Glycitop-MR 30 should be used cautiously in combination with other antidiabetic agents to prevent additive hypoglycemic effects. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Patient education on lifestyle modification, adherence to therapy, and recognition of hypoglycemia symptoms is essential for optimal outcomes. Consult a healthcare professional before initiating or discontinuing therapy.